Associations between 18-month intrahepatic fat change and 18-month anthropometric parameters and blood biomarkers changes
| Model 1 | Model 2 | Model 3 | ||||
| Beta coefficient | P value | Beta coefficient | P value | Beta coefficient | P value | |
| Anthropometric | ||||||
| ∆Weight | 0.64 | 5.3e-25 | – | – | ||
| ∆Waist circumference | 0.56 | 3.7e-19 | – | – | ||
| ∆Systolic BP | 0.17 | 0.01 | 0.10 | 0.05 | 0.07 | 0.15 |
| ∆Diastolic BP | 0.28 | 1.9e-5 | 0.16 | 0.005 | 0.11 | 0.04 |
| Glycaemic biomarkers | ||||||
| ∆Glucose | 0.22 | 0.001 | 0.11 | 0.06 | 0.08 | 0.15 |
| ∆HOMA IR | 0.26 | 8.8e-5 | 0.13 | 0.02 | 0.04 | 0.49 |
| ∆Insulin | 0.28 | 2.9e-5 | 0.14 | 0.02 | 0.03 | 0.54 |
| Lipid biomarkers | ||||||
| ∆Triglycerides | 0.38 | 5.5e-9 | 0.22 | 8.1e-5 | 0.11 | 0.056 |
| ∆Cholesterol | 0.08 | 0.30 | 0.08 | 0.16 | 0.04 | 0.41 |
| ∆HDL | −0.38 | 7.9e-9 | −0.20 | 0.001 | −0.11 | 0.07 |
| ∆LDL | 0.04 | 0.51 | 0.05 | 0.40 | 0.03 | 0.61 |
| ∆TG/HDL ratio | 0.40 | 3.3E-10 | 0.25 | 2.0e-5 | 0.14 | 0.02 |
| ∆Cholesterol/HDL ratio | 0.36 | 2.6e-8 | 0.24 | 1.4e-5 | 0.15 | 0.007 |
| Liver enzymes and hepatokines | ||||||
| ∆ALT | 0.32 | 2.0e-6 | 0.2 | 0.001 | 0.1 | 0.089 |
| ∆AST | 0.13 | 0.049 | 0.08 | 0.12 | 0.07 | 0.18 |
| ∆ALT/AST ratio | 0.36 | 6.2e-8 | 0.23 | 9.8e-5 | 0.10 | 0.069 |
| ∆ALKP | 0.03 | 0.69 | −0.001 | 0.95 | −0.008 | 0.88 |
| ∆FGF21 | 0.26 | 9.2e-5 | 0.15 | 0.01 | 0.12 | 0.03 |
| Adipokines and inflammation | ||||||
| ∆Chemerin | 0.18 | 0.007 | 0.13 | 0.02 | 0.16 | 0.001 |
| ∆Leptin | 0.15 | 0.03 | 0.06 | 0.36 | −0.08 | 0.18 |
| ∆hsCRP | 0.17 | 0.02 | 0.14 | 0.01 | 0.09 | 0.089 |
Model 1: adjusted for age, sex, baseline IHF% and intervention group.
Model 2: adjusted for age, sex, baseline IHF% intervention group, and 18-month waist circumference change.
Model 3: adjusted for age, sex, baseline IHF%, intervention group and 18-month weight change.
ALKP, alkaline phosphatase; ALT, alanine transaminase; AST, aspartate transaminase; BP, blood pressure; FGF, fibroblast growth factor; HDL, high-density lipoprotein; HOMA IR, homeostatic model assessment of insulin resistance; hsCRP, high sensitivity C reactive protein; LDL, low-density lipoprotein; TG, triglycerides.